Postmenopausal hormone replacement and cardiovascular disease: Incorporating research into practice

JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing

Volumn 33, Issue 5, 2004, Pages 648-656

  Chase, Susan K ^a   Youngkin, Ellis Quinn ^a  

^a FLORIDA ATLANTIC UNIVERSITY   (United States)

Author keywords

Cardiovascular disease; Hormone replacement therapy; Women's health

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ESTROGEN; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEDROXYPROGESTERONE ACETATE; MEVINOLIN; NORETHISTERONE ACETATE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SIMVASTATIN; TAMOXIFEN;

ARTICLE; ATHEROSCLEROSIS; BREAST CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EMBOLISM; ESTROGEN ACTIVITY; ESTROGEN THERAPY; FEMALE; HEART INFARCTION; HEPATITIS; HORMONE SUBSTITUTION; HUMAN; HYPERCOAGULABILITY; LOW DRUG DOSE; MEDICAL INFORMATION; MENOPAUSAL SYNDROME; META ANALYSIS; MUSCLE DISEASE; NONHUMAN; OSTEOPOROSIS; PRESCRIPTION; PRIMARY PREVENTION; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW; THROMBOSIS; AGED; CHEMICALLY INDUCED DISORDER; EVIDENCE BASED MEDICINE; METHODOLOGY; MIDDLE AGED; NURSE PATIENT RELATIONSHIP; NURSING; NURSING ASSESSMENT; NURSING METHODOLOGY RESEARCH; PATIENT EDUCATION; QUALITY OF LIFE; REVIEW; UNITED STATES; WOMEN'S HEALTH;

AGED; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MIDDLE AGED; NURSE-PATIENT RELATIONS; NURSING ASSESSMENT; NURSING METHODOLOGY RESEARCH; PATIENT EDUCATION; QUALITY OF LIFE; RESEARCH DESIGN; RISK FACTORS; UNITED STATES; WOMEN'S HEALTH;

EID: 16544385160     PISSN: 08842175     EISSN: None     Source Type: Journal    
DOI: 10.1177/0884217503261897     Document Type: Article

References (38)

1. Brett, K., & Madans, J. (1997). Use of postmenopausal hormone replacement therapy: Estimates from a national representative cohort study. American Journal of Epidemiology, 145, 536-545.
2. Fletcher, S. W., & Colditz, G. A. (2002). Failure of estrogen plus progesterone therapy for prevention. Journal of the American Medical Association, 288, 366-368.
3. Goldberg, N. (2002). Women are not small men: Life-saving strategies for preventing and healing heart disease in women. New York: Ballantine.
4. Gotto, A. M. (1997). Cholesterol management in theory and practice. Circulation, 96, 4424-4430.
5. Gould, A. L., Rossouw, J. E., Santanello, N. C., Heyse, J. F., & Furberg, C. D. (1998). Cholesterol reduction yields clinical benefit: Impact of statin trials. Circulation, 97, 946-952.
6. Grodstein, F., Clarkson, T. B., & Manson, J. E. (2003). Understanding the divergent data on postmenopausal hormone therapy. New England Journal of Medicine, 348, 645-650.
7. Grodstein, F., Manson, J. A., Colditz, G. A., Willett, W. C., Speizer, F. E., & Stampfer, M. J. (2000). A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Annals of Internal Medicine, 133, 933-941.
8. Haas, J. S., Kaplan, C. P., Gerstenberger, E. P., & Kerlikowske, K. (2004). Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Annals of Internal Medicine, 140, 184-188.
9. Hackley, B., & Rousseau, M. E. (2004). Managing menopausal symptoms after the Women's Health Initiative. Journal of Midwifery & Women's Health, 49, 87-95.
10. Hays, J., Ockene, J. K., Brunner, R. L., Kotchen, J. M., Manson, J. E., Patterson, R. E., et al. (2003). Effects of estrogen plus progestin on health-related quality of life. New England Journal of Medicine, 348, 1839-1854.
11. Herrington, D. M. (2003). Hormone replacement therapy and heart disease: Replacing dogma with data. Circulation, 107, 2-4.
12. Herrington, D. M., Espeland, M. A., Crouse, J. R., III, Robertson, J., Riley, W. A., McBurnie, M. A., et al. (2001). Estrogen replacement and brachial artery flow-mediated vasodilation in older women. Arteriosclerosis, Thrombosis and Vascular Biology, 21, 1955-1961.
13. Herrington, D. M., & Howard, T. D. (2003). From presumed benefit to potential harm - Hormone therapy and heart disease. New England Journal of Medicine, 349, 519-522.
14. Herrington, D. M., Werbel, B. L., Riley, W. A., Pusser, B. E., & Morgan, T. M. (1999). Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease. Journal of the American College of Cardiology, 33, 2030-2037.
15. Hodis, H. N., Mack, W. J., Azen, S. P., Lobo, R. A., Shoupe, D., Mahrer, P. R., et al. (2003). Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. New England Journal of Medicine, 349, 535-545.
16. Hulley, S., Grady, D., Bush, T., Furberg, C., Herrington, D., Riggs, B., et al. for the Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. (1998). Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. Journal of the American Medical Association, 280, 605-613.
17. Humphrey, L. L., Chan, B. K. S., & Sox, H. C. (2002). Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Annals of Internal Medicine, 137, E273-E289.
18. Leinwald, L. A. (2003). Sex is a potent modifier of the cardiovascular system. Journal of Clinical Investigation, 112, 302-307.
19. Love, R. R., Wiebe, D. A., Feyzi, J. M., Newcomb, P. A., & Chappell, R. J. (1994). Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. Journal of the National Cancer Institute, 86, 1534-1539.
20. Manson, J. E., Hsia, J., Johnson, K. C., Rossouw, J. E., Assaf, A. R., Lasser, N. L., et al. (2003). Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine, 349, 523-534.
21. Manson, J. E., & Martin, K. A. (2001). Clinical practice: Postmenopausal hormone-replacement therapy. New England Journal of Medicine, 345, 34-40.
22. Mendelsohn, M. E., & Karas, R. H. (1999). Mechanisms of disease: The protective effects of estrogen on the cardiovascular system. New England Journal of Medicine, 340, 1801-1811.
23. Michels, K. B., & Manson, J. E. (2003). Postmenopausal hormone therapy: A reversal of fortune. Circulation, 107, 1830-1833.
24. Mosca, L., Barrett-Connor, E., Wenger, N. K., Collins, P., Grady, D., Kornitzer, M., et al. (2001). Design and methods of the Raloxifene Use for The Heart (RUTH) study. American Journal of Cardiology, 88, 392-395.
25. Mosca, L., Collins, R., Herrington, D. M., Mendelsohn, M. E., Pasternak, R. C., Robertson, R. M., et al. (2001). Hormone replacement therapy and cardiovascular disease: A statement for healthcare professionals from the American Heart Association. Circulation, 104, 499-503.
26. National Cholesterol Education Program. (2001). Third Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) National Heart Lung and Blood Institute. Retrieved September 30, 2003, from http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3_rpt.htm
27. National Institutes of Health. (2004). NIH asks participants in Women's Health Initiative Estrogen-Alone Study to stop study pills, begin follow-up phase. Retrieved March 25, 2004, from www.nhlbi.nih.gov/new/press/04-03-02.htm
28. North American Menopause Society. (2003). Role of progestogen in hormone therapy for postmenopausal women. Position statement of the North American Menopause Society. Menopause, 10, 113-132.
29. Penckofer, S. M., Hackbarth, D., & Schwertz, D. W. (2003). Estrogen plus progestin therapy: The cardiovascular risks exceed the benefits. Journal of Cardiovascular Nursing, 18, 347-355.
30. Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000). C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. New England Journal of Medicine, 342, 836-843.
31. Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., Kooperberg, C., Stefanick, M. L., et al. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. Journal of the American Medical Association, 288, 321-333.
32. Sbarouni, E., Kyriakides, Z. S., & Kremastinos, D. T. (1998). The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease. Journal of the American College of Cardiology, 32, 1244-1250.
33. Stampfer, M., Colditz, G., Willett, W., Manson, J. E., Rosner, B., Speizer, F. E., et al. (1991). Postmenopausal estrogen therapy and cardiovascular disease: Ten-year follow-up from the Nurses' Health Study. New England Journal of Medicine, 325, 756-762.
34. U.S. Department of Health and Human Services (2003). The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. NIH Publication No. 03-5233.
35. Voelker, R. (2002). Questions about hormone therapy remain puzzling. Journal of the American Medical Association, 288, 2395-2396.
36. Walsh, B. W., Kuller, L. H., Wild, R. A., Paul, S., Farmer, M., Lawrence, J. B., et al. (1998). Effects of raloxifene on serum lipids and coagulation factors in health postmenopausal women. Journal of the American Medical Association, 279, 1445-1451.
37. Walsh, B. W., Paul, S., Wild, R. A., Dean, R. A., Tracy, R. P., Cox, D. A., et al. (2000). The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: A randomized, controlled trial. Journal of Clinical Endocrinology and Metabolism, 85, 214-218.
38. Wilson, R. (1968). Feminine forever. New York: M. Evans & Company.